Top Cancer Drug Companies (2026 Update): Leaders by Revenue, Pipeline, and Growth
The global oncology market is entering a new phase in 2026—defined by immunotherapy dominance, CAR-T expansion, and next-gen targeted therapies . While legacy giants still dominate revenue, earnings reports from Q1 2026 show a clear shift toward innovation-driven growth and aggressive M&A activity . This updated ranking incorporates: Latest Q1 2026 earnings data Oncology revenue trends Pipeline strength and strategic positioning Competitive threats (patent cliffs, biosimilars) Related: Latest Breakthroughs in Cancer Treatment 1. Merck & Co. Merck (MRK) reported strong Q4 2025 results on Feb 3, 2026, with revenue of $16.4 billion (5% increase year-over-year) and adjusted EPS of $2.04, beating analyst expectations, according to CNBC . Merck & Co. (MRK) is scheduled to release its Q1 2026 earnings before the market opens on April 30, 2026, with a consensus ...